Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease.The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern....
Source LinkAnnovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease.The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern....
Source Link
Comments